Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Unanswered questions and unmet needs in prostate cancer

John Michael Bryant, Moffitt Cancer Center, Tampa, FL, discusses the unmet needs of prostate cancer. Even with the current standard of care consisting of androgen deprivation therapy (ADT), external beam RT (EBRT), and high dose rate brachytherapy (HDR), patients with high-risk disease, high rates of distant metastatic disease still occurs, resulting in poor patient outcomes. A Phase II trial (NCT03543189) assessing the combination of nivolumab with standard of care (SOC) in the management of grade group 5 (GG5) prostate cancer is evaluating whether the addition of immunotherapy can improve outcomes for this patient population. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.